electroCore’s gammaCore Sapphire Enters PTSD Adjunctive Treatment Study

Event summary

  • electroCore’s gammaCore Sapphire nVNS device is being tested as an adjunctive treatment for PTSD symptoms in a 10-month study led by Acacia Clinics and the Vagus Nerve Society.
  • The study will enroll up to 40 subjects aged 18–70, with primary efficacy measured by the CAPS-5 scale at 12 weeks.
  • electroCore is providing educational grants and devices, while Acacia Clinics’ Danielle DeSouza, PhD, oversees the research.
  • PTSD affects 6% of the population, with only one-third achieving full remission under current treatments.

The big picture

electroCore’s study represents a strategic push into mental health, an area with high unmet need and limited effective adjunctive therapies. The collaboration with Acacia Clinics and the Vagus Nerve Society strengthens its position in neuromodulation, but success hinges on proving gammaCore Sapphire’s efficacy in a competitive landscape dominated by pharmaceutical and device-based interventions. If validated, this could open a new revenue stream beyond chronic pain.

What we're watching

Clinical Validation
Whether gammaCore Sapphire demonstrates statistically significant efficacy in reducing PTSD symptoms, potentially expanding its regulatory and commercial applications.
Market Expansion
The pace at which electroCore can leverage positive study results to position nVNS as a mainstream adjunctive therapy for PTSD.
Competitive Positioning
How this study impacts electroCore’s standing against traditional and emerging neuromodulation treatments in mental health.

Related topics

Partnership Medical Devices